Business
CTA for SCIB1 melanoma vaccine
CTA for SCIB1 melanoma vaccine.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n2 February 2010\n\n GB00B39J5N63\n\n Scancell Holdings Plc \n\n (`Scancell Holdings' or the `Company') \n\n Clinical Trial Application for SCIB1 melanoma vaccine \n\nScancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer\nvaccines, is pleased to announce that its proposal to conduct a Phase I\nclinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the\ntreatment of melanoma, was submitted to the Gene Therapy Advisory Committee\n(`GTAC') on 29 December 2009. In addition, Scancell and its partner Ichor\nMedical Systems (`Ichor') submitted parallel applications to the Medicines\nDivision and to the Devices Division of the Medicines and Healthcare products\nRegulatory Agency (`MHRA') on29January 2010 requesting approvals for the\nclinical trial of SCIB1 and for the use of Ichor's TriGrid™ electroporation\ndelivery device to administer SCIB1 to participating patients, respectively.\n\nSCIB1 is a novel DNA ImmunoBody® vaccine being developed using Scancell's\npatented ImmunoBody® technology for the treatment of melanoma. ImmunoBody®\nvaccines generate the high-avidity T-cells that kill cancer cells, which may\novercome the current limitations of most cancer vaccines. In vivo\nelectroporation is widely regarded as an effective method of enhancing the\npotency of DNA vaccines by up to 100 -fold compared to conventional methods of\ndelivery. Scancell is confident that TriGrid™ will provide the most effective\ndelivery system for its SCIB1 melanoma vaccine as it enters clinical trials.\n\nAdvanced melanoma currently has a very poor prognosis with late stage (stage\nIV) disease having a median survival of approximately six months. According to\nthe World Health Organisation, 132,000 melanoma skin cancers occur globally\neach year and the incidence is increasing, especially in the United States,\nEurope and Australia.\n\nDavid Evans, Chairman of Scancell, commented:\n\n\"Scancell's CTA submission and proposal to GTAC to conduct the Phase I clinical\ntrial for our first therapeutic cancer vaccine marks a significant step for the\nCompany and we look forward to reporting on its progress. We are confident\nthat, subject to regulatory and ethical approvals, the Phase I clinical trial\nfor SCIB1 will be on target to commence in Q2 2010.\"\n\nA copy of this announcement is available for download on ...